EMA Authorised: Sitagliptin / Metformin hydrochloride Mylan (sitagliptin hydrochloride monohydrate;metformin hydrochloride) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The EMA authorised a fixed-dose combination of sitagliptin and metformin hydrochloride from Mylan for the treatment of type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin/metformin hydrochloride (sitagliptin; metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Mylan Pharmaceuticals Limited. Decision date: 30/09/2025